NOVEL METHODOLOGIES AND IVIVC APPROACHES TO ASSESS BIOEQUIVALENCE OF TOPICAL DRUG -
Generic drugs now represent the major part of the US pharmaceutical market. They are an
attractive alternative to brand products for consumers because they are bioequivalent and
therefore the same in terms of quality, safety and efficacy, but available at a considerably
reduced cost. However, there are still products for which no or few generic alternatives are
available. A big barrier to generic drug development is that the sponsor must demonstrate
that their product is bioequivalent to the reference-listed drug (RLD). This is a particular
challenge for the development of dermatological drugs because these drugs act locally,
whereas most tests for bioequivalence (BE) use blood measurements. Thus, manufacturers
must rely on clinical endpoint studies, which are not only expensive and time consuming, but
also rather unreliable. Hence, there is an urgent need for new, more efficient ways to
demonstrate BE of topical drugs. In particular, in vitro methods that correlate well with the in
vivo situation would significantly facilitate the development of topical generic drugs.
We will investigate in vitro and in vivo methods to show BE of topical products and will
establish in vitro - in vivo correlations (IVIVC) at the level of pharmacokinetics in the dermis.
First, we will conduct a clinical study to assess BE and non-BE in skin using dermal open
flow microperfusion (dOFM) according to GCP and GLP. The results will serve as a "gold
standard" for the in vivo situation in the dermis, and as a reference for validating all present
and future in vitro methods for their ability to predict the in vivo situation.
Secondly, we will examine in vitro methods to establish BE, starting with the only FDA-
accepted in vitro approach as per the "FDA Draft Guidance on Acyclovir". We will then
investigate innovative in vitro systems based on dOFM as a new in vitro approach for BE.
We will use Zovirax 5% ointment (RLD) to demonstrate BE and Zovirax 5% creme to
demonstrate non-BE against Zovirax 5% ointment. The same formulations will be used to
demonstrate BE and non-BE in all in vitro and in vivo systems. All experiments will be
performed under quality-controlled standards (ISO 9001, GCP, GLP. EN ISO 13485). One
analytical HPLC-MS/MS method suitable for all project samples will be developed and
validated according to ICH guidelines in a GLP-certified laboratory. All results of the BE and
non-BE pairs using different methods will be analyzed for their predictive power. By cross-
referencing the results, we plan to correlate in vitro with in vivo data to establish IVIVC.
